Biotech Values

[lgonber]

OXGN: thanks Dew. I actually came across this company recently, as other investors pointed out to me that there could be value and may be is now time for a reversal. What are your thoughts on the following comments:
They are setting up a lay down PIII SPA for first chemo free treatment of ovarian cancer.
They got a favorable trial design from FDA for phase 3 in ovarian cancer. Their drug plus avastin doubled PFS against avastin alone, and could become the new paradigm for treating platimum resistance ovarian cancer.
The p3 will test fosbretabulin and avastin in combination against chemo, and a separate mono arm for avastin as a point of reference. Also, exciting stuff testing fosbretabulin in AML (seems to clear AML cells from the bone marrow) and other cancers.
The primary endpoint in the PIII design is PFS. In the p-rOC group, they already gained 95% PFS+ vs Avastin alone. They are using the A + F combination to compare vs. chemo alone.. and Avastin alone. SPA on it's way. Market is at 50% of the 70,000 diagnosed with OC each year, plus there are over 300,000 existing patients on chemo now. OXGN's drug is non-toxic. No chemo side effects.
They are partnered combination drug: None other than Avastin.

The mechanism in ovarian is VDA. Targeted vascular disruption agent. Takes out blood vessels in tumor tissue. The AML compound, is dual mechanism. VDA and cyto ros. Even more potent.
Decision Resources reported that 70% of docs used Avastin in ovarian, before it was approved last November.

An estimated 85% of patients with epithelial ovarian cancer who achieve a full remission following first-line therapy will develop recurrent disease. Although each subsequent line of therapy is characterized by shorter disease-free intervals, median survival for these patients ranges from 12 months to 24 months.
From Aurelia notes:
Platinum-free interval is a strong predictor of treatment success in recurrent ovarian cancer.1 Patients whose disease relapses within 6 months after platinum-containing therapy are categorized as having platinum-resistant disease. At first relapse, approximately 25% of patients have platinum-resistant ovarian cancer; almost all patients with recurrent disease ultimately develop platinum resistance.

So, 85% will recur, and nearly all of those will go p-r. 70,000/yr in US and EU, with ~300,000 on chemo now.

The AML drug is OXi-4503. More potent, dual action.